Literature DB >> 16258715

Cardiac remodeling as therapeutic target: treating heart failure with Cardiac Support Devices.

Douglas L Mann1.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16258715     DOI： 10.1007/s10741-005-4635-z

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.214


× No keyword cloud information.
  10 in total

1.  Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction.

Authors:  M A Quiñones; B H Greenberg; H A Kopelen; C Koilpillai; M C Limacher; D M Shindler; B J Shelton; D H Weiner
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

2.  Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure.

Authors:  Martin G St John Sutton; Ted Plappert; William T Abraham; Andrew L Smith; David B DeLurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Westby G Fisher; Myrvin Ellestad; John Messenger; Kristin Kruger; Kathryn E Hilpisch; Michael R S Hill
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

3.  Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction.

Authors:  R S Vasan; M G Larson; E J Benjamin; J C Evans; D Levy
Journal:  N Engl J Med       Date:  1997-05-08       Impact factor: 91.245

Review 4.  Mechanisms and models in heart failure: the biomechanical model and beyond.

Authors:  Douglas L Mann; Michael R Bristow
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

5.  Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy.

Authors:  P S Douglas; R Morrow; A Ioli; N Reichek
Journal:  J Am Coll Cardiol       Date:  1989-02       Impact factor: 24.094

6.  Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition.

Authors:  J N Cohn
Journal:  Circulation       Date:  1995-05-15       Impact factor: 29.690

7.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

8.  Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

Authors:  R N Doughty; G A Whalley; G Gamble; S MacMahon; N Sharpe
Journal:  J Am Coll Cardiol       Date:  1997-04       Impact factor: 24.094

9.  Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.

Authors:  Maylene Wong; Lidia Staszewsky; Roberto Latini; Simona Barlera; Robert Glazer; Nora Aknay; Allen Hester; Inder Anand; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

10.  Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

Authors:  M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690
  10 in total
  2 in total

1.  Mechanisms of Post-Infarct Left Ventricular Remodeling.

Authors:  Brent A French; Christopher M Kramer
Journal:  Drug Discov Today Dis Mech       Date:  2007

Review 2.  Molecular mechanisms of sacubitril/valsartan in cardiac remodeling.

Authors:  Nor Hidayah Mustafa; Juriyati Jalil; Satirah Zainalabidin; Mohammed S M Saleh; Ahmad Yusof Asmadi; Yusof Kamisah
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.